FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Omeprazole

Drug and asset intelligence for Omeprazole with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Mechanism of action

Proton Pump Inhibitor

Recent signals(2)

RegulatoryAugust 1, 2026

FDA Submission Update for Omeprazole by Dr. Reddy's

Reddy's has submitted a supplemental application for Omeprazole (ANDA207740) with an unknown review priority.

StrategyJuly 11, 2026

FDA Approval Update for Omeprazole ANDA207740 by Dr. Reddy's

Reddy's has submitted an Abbreviated New Drug Application (ANDA) for Omeprazole, currently under review.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Omeprazole

July 11, 2026 · N/A

Topline Data

— Omeprazole

July 8, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Gastroenterology →

Gastroenterology · Proton Pump Inhibitor →

Proton Pump Inhibitor →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.